DEFA14A: Coherus BioSciences to Divest UDENYCA Franchise to Intas Pharmaceuticals for up to $558.4 Million

Coherus BioSciences will divest its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million, allowing Coherus to focus on its immuno-oncology pipeline.

Summary

• Coherus BioSciences has agreed to sell its UDENYCA franchise to Intas Pharmaceuticals for a total consideration of up to $558.4 million.
• The deal includes an upfront payment of $483.4 million in cash, subject to inventory adjustments, and up to $75 million in potential milestone payments based on net sales.
• Coherus will use the proceeds to repay $230 million in convertible notes due in April 2026 and $49.1 million to buy out royalty obligations related to UDENYCA.
• The transaction is expected to close in the first quarter of 2025, pending shareholder and regulatory approvals.
• The divestiture will allow Coherus to focus on its immuno-oncology portfolio, including LOQTORZI, casdozokitug, and CHS-114.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the strategic divestiture, debt reduction, and focus on innovative programs. The financial benefits and future growth potential are highlighted, leading to a strong positive sentiment.

Positives

• The divestiture allows Coherus to focus on its innovative immuno-oncology programs.
• The transaction will significantly improve Coherus's capital structure by paying off convertible notes.
• Coherus expects to realize substantial cost savings by transferring employees and eliminating UDENYCA-related overhead.
• The company plans to use tax attributes to offset substantially all U.S. federal income taxes related to the divestiture.
• The company's cash runway is projected to exceed two years post-close, past key data readouts expected in 2026.

Negatives

• Coherus is losing a revenue stream from the UDENYCA franchise.
• The transaction is subject to customary closing conditions, including shareholder and regulatory approvals, which could delay or prevent the deal from closing.
• There is a risk that the milestone payments may not be achieved if UDENYCA sales targets are not met.

Risks

• The transaction is subject to shareholder and regulatory approvals, which could delay or prevent the deal from closing.
• There is a risk that the milestone payments may not be achieved if UDENYCA sales targets are not met.
• The company's future success is dependent on the success of its immuno-oncology pipeline, which is still in development.
• There is a risk that competing offers could be made by third parties.
• The company may not realize the anticipated benefits of the proposed transaction in the time frame expected, or at all.

Future Outlook

Coherus plans to focus on its immuno-oncology portfolio, including LOQTORZI, casdozokitug, and CHS-114, with key data readouts expected in 2026. The company expects to realize substantial cost savings and improve its capital structure.

Management Comments

• Denny Lanfear, Coherus Chairman and CEO, stated that the divestiture allows the company to focus on its innovative immuno-oncology portfolio and strengthen its financial position.
• He also mentioned that the transaction allows Coherus to monetize the value of the UDENYCA franchise to maximize the opportunity for LOQTORZI and advance the development of the I-O pipeline.

Industry Context

The divestiture reflects a trend in the biopharmaceutical industry where companies are focusing on core therapeutic areas and divesting non-core assets to improve financial positions and focus on innovative pipelines. This move allows Coherus to compete more effectively in the immuno-oncology space.

Comparison to Industry Standards

• The divestiture of a non-core asset for a significant upfront payment and potential milestones is a common strategy in the biopharmaceutical industry, similar to other companies that have divested assets to focus on core therapeutic areas.
• The valuation of the UDENYCA franchise at up to $558.4 million is within the range of similar transactions for established biosimilar products.
• The use of proceeds to pay down debt and buy out royalty obligations is a typical move to improve financial stability and reduce future liabilities, similar to other companies that have restructured their balance sheets after significant transactions.
• The focus on immuno-oncology is aligned with the current industry trend towards developing innovative cancer therapies, with companies like Bristol Myers Squibb, Merck, and Roche also heavily investing in this area.

Stakeholder Impact

• Shareholders will benefit from the improved financial position and focus on innovative programs.
• Employees may be affected by the transfer of some positions to Intas.
• Customers will see a change in the ownership of the UDENYCA franchise.
• Creditors will benefit from the repayment of the convertible notes.

Next Steps

• Coherus will file a proxy statement with the SEC and mail it to shareholders.
• Coherus shareholders will vote on the proposed divestiture.
• The transaction is expected to close by the end of Q1 2025.
• Coherus will initiate a process to fully repay the outstanding convertible notes.
• Coherus will initiate a Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in first-line (1L) HCC in Q4 2024.
• Coherus will report Phase 1 monotherapy biopsy data as well as CHS-114/toripalimab combination safety data in head and neck squamous cell carcinoma (HNSCC) in 1H 2025.
• Coherus will initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L head and neck squamous cell carcinoma (HNSCC) in Q1 2025.
• Coherus will initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025.

Key Dates

Keywords

UDENYCA, Coherus BioSciences, Intas Pharmaceuticals, immuno-oncology, divestiture, LOQTORZI, casdozokitug, CHS-114, asset purchase agreement, milestone payments, convertible notes, biosimilar, PD-1 inhibitor, cancer treatment